Member of Lyonbiopole
NH TherAguix is a late-stage biotech company developing AGuIX® to treat tumours and metastases in patients treated by radiotherapy. It is estimated that c.60% of cancer patients undergo radiotherapy treatment today.
AGuIX® is currently assessed in 4 Phase II randomized trials in brain metastases using either whole brain radiation therapy (NANORAD2, CHUGA, Grenoble, France) or stereo-radiosurgery (NANOBRAINMETS, Dana Farber Brigham Cancer Center, Boston, USA), in glioblastoma (NANOGBM, multicentric, Clermont Ferrand, France) as well as in pancreatic and lung cancers (NANOSMART, Dana Farber Brigham Cancer Center, Boston, USA).
NH TherAguix was established in 2015 after 10 years of academic research in the founders’ laboratories that led to the invention of AGuIX® and the discovery of its radiosensitizing effect.
Altogether, NH TherAguix raised around €40M of dilutive and non-dilutive funds, including a €13M A series in 2019, led by Bpifrance with Arbevel, Omnes and Supernova.
Strategic application domain: Human Medicine
Application market: Oncology
Type of activity: Diagnostics, Therapeutics, Pharma or Biotech
Technologies: Drug delivery device & Technologies, Imaging, Nanotechnology
Created on dec. 15th, 2015 - 12 employees
Address
19 chemin des prés 38240 Meylan
Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.